Save 50% of the cost of category C ropinirole prescriptions by prescribing Repinex XL.2*
By prescribing Repinex® XL by brand, the average savings for ICS/ICB’s could still be approximately £49,475 per year, providing the NHS with a total potential annual prescribing cost saving of approximately £2 million.1
Repinex XL is part of the cost-saving prolonged-release product range from Aspire Pharma.
- Over 50% saving on cost of Category C Drug Tariff price;2*
- Available from all mainline wholesalers;
- High level of stockholdings;
- Price Guaranteed***
- Bioequivalent to the originator.3
Product | Category C UK Drug Tariff price | Repinex XL price |
---|---|---|
Ropinirole prolonged-release tablets 2mg x 28 | £12.54 | £6.20 |
Ropinirole prolonged-release tablets 4mg x 28 | £25.09 | £12.50 |
Ropinirole prolonged-release tablets 8mg x 28 | £42.11 | £21.00 |
*50% saving on the cost of Category C ropinirole prolonged-release tablets in the UK Drug Tariff. **Savings based on market data in reference 1 for 42 ICS/ICB’s switching their generic and brand originator 2,4 and 8mg ropinirole prolonged-release tablet prescriptions to Repinex XL. ***No change in price subject to no material change to the products or Category C of the UK Drug Tariff until the 2026 VPAG review.
References 1) Insypher 10100831045 v 17.0 January 2024 GPPLPD Date Range: Jul-23 – Sep-23 2) February 2024 UK Drug Tariff. 3) Data on file. 1010067149 v 6.0 September 2023.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148
For more information about Repinex XL, please click here for the prescribing information.